Ethel Weld, MD

CRS:

JHU

Role:

Email:

eweld@jhmi.edu
  • Protocol chair, IMPAACT 2005
  • Protocol vice-chair, IMPAACT 2022
  • Member, Clinical Pharmacology Advisory Group of the ACTG Laboratory Steering Committee (2018-Present)
  • Member, ACTG Antiretroviral Therapy Strategies Transformative Science Group Less Frequent Dosing ART Working Group
  • Member, Pharmacology Core, HPTN Laboratory Core
  • Member, TB in Pregnancy Working Group
  • Protocol pharmacologist for HPTN 086, IMPAACT CAP 544, IMPAACT CAP 543

Categories

Leadership Committees
CRS
Roles

Clinical Trials

The Pharmacokinetics, Safety and Acceptability of New...

PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

Identification of Biomarkers That Can Predict Progression...

Purpose: The C-TRIUMPH study has identified 20 household contacts (HHC), who have progressed to active TB from its HHCs cohort...

Read More

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More

A5349: Rifapentine-containing treatment shortening regimens...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

Read More